Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $885000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 31.5% to $885000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, down 22.35% year-over-year, with the annual reading at $5.4 million for FY2025, 20.04% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $885000.0 at Aytu Biopharma, up from $803000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $3.3 million in Q2 2021, with the low at $803000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.9 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 71.85% in 2021, then plummeted 40.18% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $2.7 million in 2021, then decreased by 17.53% to $2.2 million in 2022, then dropped by 18.81% to $1.8 million in 2023, then dropped by 27.86% to $1.3 million in 2024, then crashed by 31.5% to $885000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $885000.0, $803000.0, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.